Published in Eur J Nucl Med Mol Imaging on January 09, 2015
Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. Eur J Nucl Med Mol Imaging (2015) 0.84
Updated overview of current biomarkers in head and neck carcinoma. World J Methodol (2016) 0.82
Surveillance radiologic imaging after treatment of oropharyngeal cancer: a review. World J Surg Oncol (2015) 0.78
Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol (2015) 0.77
Radiation dose escalation based on FDG-PET driven dose painting by numbers in oropharyngeal squamous cell carcinoma: a dosimetric comparison between TomoTherapy-HA and RapidArc. Radiat Oncol (2017) 0.75
The promise of multiparametric imaging in oncology: how do we move forward? Eur J Nucl Med Mol Imaging (2016) 0.75
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet (2006) 6.67
Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys (2000) 4.99
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol (2005) 3.86
Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit (2009) 3.32
Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol (2005) 2.65
Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med (2002) 2.54
Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2005) 2.41
Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology (2004) 2.40
18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst (2008) 2.32
A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging (2007) 2.32
Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes. J Nucl Med (2014) 2.19
The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys (2005) 1.99
Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol (2003) 1.95
FDG-PET in radiotherapy treatment planning: Pandora's box? Int J Radiat Oncol Biol Phys (2004) 1.91
Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol (2006) 1.91
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2011) 1.82
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med (2005) 1.81
Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET/CT fusion. Int J Radiat Oncol Biol Phys (2006) 1.79
Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res (2012) 1.76
18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med (2013) 1.69
The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer (2004) 1.67
FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck (2002) 1.66
Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial. Head Neck (2010) 1.62
Combined 18F-FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2008) 1.53
Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys (2004) 1.52
18F-FDG uptake in reactive neck lymph nodes of oral cancer: relationship to lymphoid follicles. J Nucl Med (2008) 1.49
Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.46
Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck (2005) 1.45
Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med (2014) 1.43
Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol (2011) 1.35
Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Laryngoscope (2009) 1.33
Inter-observer variability in the delineation of pharyngo-laryngeal tumor, parotid glands and cervical spinal cord: comparison between CT-scan and MRI. Radiother Oncol (2005) 1.32
Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol (2006) 1.30
FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol (2012) 1.24
Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med (2009) 1.22
Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother Oncol (2010) 1.15
Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol (2012) 1.14
Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol (2007) 1.11
Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2007) 1.09
Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur J Nucl Med Mol Imaging (2011) 1.09
18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med (2010) 1.05
Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging (2011) 1.05
Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. Radiother Oncol (2011) 1.02
Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med (2007) 1.01
Laryngeal tumor volume measurements determined with CT: a study on intra- and interobserver variability. Int J Radiat Oncol Biol Phys (1998) 1.01
Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? Radiother Oncol (2012) 0.99
Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. Radiother Oncol (2008) 0.99
The value of (18)F-FDG PET/CT for the detection of distant metastases in high-risk patients with head and neck squamous cell carcinoma. Oral Oncol (2011) 0.95
Additional diagnostic value of (18)F-FDG PET-CT in detecting retropharyngeal nodal metastases. Otolaryngol Head Neck Surg (2009) 0.94
Can 18-FDG-PET during radiotherapy replace post-therapy scanning for detection/demonstration of tumor response in head-and-neck cancer? Int J Radiat Oncol Biol Phys (2010) 0.94
A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging (2014) 0.93
Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol (2012) 0.90
Role of (18)F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma. World J Radiol (2014) 0.89
Usefulness of 3'-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. J Nucl Med (2012) 0.88
Volumetric PET/CT parameters predict local response of head and neck squamous cell carcinoma to chemoradiotherapy. Cancer Med (2014) 0.87
Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol (2014) 0.87
PET and PET/CT of the neck lymph nodes improves risk prediction in patients with squamous cell carcinoma of the oral cavity. J Nucl Med (2011) 0.86
Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome. Eur J Nucl Med Mol Imaging (2013) 0.84
Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control. Radiother Oncol (2014) 0.83
18F-FET PET/CT in advanced head and neck squamous cell carcinoma: an intra-individual comparison with 18F-FDG PET/CT. Mol Imaging Biol (2011) 0.83
Prognostic value of tumour blood flow, [¹⁸F]EF5 and [¹⁸F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy. Eur J Nucl Med Mol Imaging (2014) 0.82
Asphericity of pretherapeutic tumour FDG uptake provides independent prognostic value in head-and-neck cancer. Eur Radiol (2014) 0.81
Advances in imaging in the work-up of head and neck cancer patients. Oral Oncol (2009) 0.81
Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma. Mol Imaging Biol (2008) 0.81
FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma. AJR Am J Roentgenol (2014) 0.81
The role of CT and ¹⁸F-FDG PET in managing the neck in node-positive head and neck cancer after chemoradiotherapy. Acta Otolaryngol (2009) 0.80
18FDG PET-CT for distant metastases in patients with recurrent head and neck cancer after definitive treatment. A meta-analysis. Oral Oncol (2013) 0.80
Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro. Anticancer Res (2013) 0.80
Pathology-based validation of FDG PET segmentation tools for volume assessment of lymph node metastases from head and neck cancer. Eur J Nucl Med Mol Imaging (2013) 0.80
Concern Positron emission tomography in the detection of occult primary head and neck carcinoma: a retrospective study. Head Neck Oncol (2012) 0.80
Implementation of hypoxia PET imaging in radiation therapy planning. Q J Nucl Med Mol Imaging (2013) 0.79
Application of fluorodeoxyglucose positron emission tomography in the management of head and neck cancers. World J Radiol (2014) 0.79
The use of multiple time point dynamic positron emission tomography/computed tomography in patients with oral/head and neck cancer does not predictably identify metastatic cervical lymph nodes. J Oral Maxillofac Surg (2012) 0.78
First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. J Nucl Med (2014) 0.78
Preoperative predictive model of cervical lymph node metastasis combining fluorine-18 fluorodeoxyglucose positron-emission tomography/computerized tomography findings and clinical factors in patients with oral or oropharyngeal squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol (2012) 0.78
Performance of 18F-FDG PET/contrast-enhanced CT in the staging of squamous cell carcinoma of the oral cavity and oropharynx. Int J Oral Maxillofac Surg (2011) 0.77
Functional target volume delineation for radiation therapy on the basis of positron emission tomography and the correlation with histopathology. Q J Nucl Med Mol Imaging (2010) 0.76
Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer from Ontario and guidelines in general--some observations. Clin Oncol (R Coll Radiol) (2013) 0.76
18F-FDG-PET/CT for the assessment of the contralateral neck in patients with head and neck squamous cell carcinoma. Laryngoscope (2013) 0.75
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol (2012) 3.06
Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol (2010) 2.61
Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology (2004) 2.40
A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging (2007) 2.32
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol (2008) 2.03
Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol (2003) 1.95
Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res (2004) 1.71
Rotterdam and Brussels CT-based neck nodal delineation compared with the surgical levels as defined by the American Academy of Otolaryngology-Head and Neck Surgery. Int J Radiat Oncol Biol Phys (2004) 1.69
Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res (2005) 1.65
Comparison of 12 deformable registration strategies in adaptive radiation therapy for the treatment of head and neck tumors. Radiother Oncol (2008) 1.62
Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res (2006) 1.62
Glucocorticoids modulate tumor radiation response through a decrease in tumor oxygen consumption. Clin Cancer Res (2007) 1.57
Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models. Radiother Oncol (2010) 1.54
Atlas-based delineation of lymph node levels in head and neck computed tomography images. Radiother Oncol (2008) 1.53
Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.46
Selective neck dissection in the management of the neck after (chemo)radiotherapy for advanced head and neck cancer. Proposal for a classification update. Head Neck (2010) 1.42
A pre-clinical assessment of an atlas-based automatic segmentation tool for the head and neck. Radiother Oncol (2009) 1.38
Gradient-based delineation of the primary GTV on FDG-PET in non-small cell lung cancer: a comparison with threshold-based approaches, CT and surgical specimens. Radiother Oncol (2010) 1.34
Inter-observer variability in the delineation of pharyngo-laryngeal tumor, parotid glands and cervical spinal cord: comparison between CT-scan and MRI. Radiother Oncol (2005) 1.32
Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res (2003) 1.32
Adaptive radiotherapy of head and neck cancer. Semin Radiat Oncol (2010) 1.31
Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation. Radiother Oncol (2010) 1.16
Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int J Radiat Oncol Biol Phys (2005) 1.15
Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol (2007) 1.15
The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncol (2011) 1.09
Adaptive functional image-guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort? Radiother Oncol (2011) 1.05
Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J (2002) 1.03
Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (2012) 1.00
The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol (2008) 0.97
A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach. Radiother Oncol (2013) 0.97
Strategies to reduce long-term postchemoradiation dysphagia in patients with head and neck cancer: an evidence-based review. Head Neck (2013) 0.96
Impact of cyclic hypoxia on HIF-1alpha regulation in endothelial cells--new insights for anti-tumor treatments. FEBS J (2008) 0.96
Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy. Radiat Res (2009) 0.96
Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. Cancer Res (2006) 0.95
Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res (2011) 0.95
Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect. Cancer Res (2005) 0.95
A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging (2014) 0.93
Edge-preserving filtering of images with low photon counts. IEEE Trans Pattern Anal Mach Intell (2008) 0.93
Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies. Radiother Oncol (2006) 0.93
Clinical use of PET-CT data for radiotherapy planning: what are we looking for? Radiother Oncol (2010) 0.92
Evaluation of a multimodality image (CT, MRI and PET) coregistration procedure on phantom and head and neck cancer patients: accuracy, reproducibility and consistency. Radiother Oncol (2003) 0.92
Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res (2004) 0.92
Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res (2002) 0.92
Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin Cancer Res (2006) 0.92
Carotid body paragangliomas: a systematic study on management with surgery and radiotherapy. Eur Arch Otorhinolaryngol (2013) 0.92
Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol Cancer Ther (2006) 0.90
Reprogramming of tumor metabolism by targeting mitochondria improves tumor response to irradiation. Acta Oncol (2014) 0.89
Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry. Radiother Oncol (2012) 0.89
Evaluation of the radiobiological impact of anatomic modifications during radiation therapy for head and neck cancer: can we simply summate the dose? Radiother Oncol (2010) 0.89
Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice. Contrast Media Mol Imaging (2013) 0.87
Tumour control probability derived from dose distribution in homogeneous and heterogeneous models: assuming similar pharmacokinetics, (125)Sn-(177)Lu is superior to (90)Y-(177)Lu in peptide receptor radiotherapy. Phys Med Biol (2012) 0.86
[18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur J Nucl Med Mol Imaging (2008) 0.86
Immobilization device for in vivo and in vitro multimodality image registration of rodent tumors. Radiother Oncol (2008) 0.86
Captopril and S-nitrosocaptopril as potent radiosensitizers: Comparative study and underlying mechanisms. Cancer Lett (2010) 0.85
Evaluation of MVCT protocols for brain and head and neck tumor patients treated with helical tomotherapy. Radiother Oncol (2009) 0.85
First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPI-II. Radiother Oncol (2010) 0.85
Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome. Eur J Nucl Med Mol Imaging (2013) 0.84
[(18) F]CuCF3 : a [(18) F]trifluoromethylating agent for arylboronic acids and aryl iodides. Chemistry (2014) 0.84
Regarding Davis et al.: Assessment of (18)F PET signals for automatic target volume definition in radiotherapy treatment planning. Radiother Oncol (2007) 0.84
Generation of prescriptions robust against geometric uncertainties in dose painting by numbers. Acta Oncol (2014) 0.84
Nitric oxide-mediated increase in tumor blood flow and oxygenation of tumors implanted in muscles stimulated by electric pulses. Int J Radiat Oncol Biol Phys (2003) 0.83
A proposal for redefining the boundaries of level V in the neck: is dissection of the apex of level V necessary in mucosal squamous cell carcinoma of the head and neck? Arch Otolaryngol Head Neck Surg (2002) 0.82
Nitric oxide as a radiosensitizer: evidence for an intrinsic role in addition to its effect on oxygen delivery and consumption. Int J Cancer (2004) 0.82
Anatomical bases for the radiological delineation of lymph node areas. Major collecting trunks, head and neck. Radiother Oncol (2007) 0.82
Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models. Radiother Oncol (2008) 0.82
Intestinal crypt regeneration in mice: a biological system for quality assurance in non-conventional radiation therapy. Radiother Oncol (2004) 0.81
Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging. Contrast Media Mol Imaging (2013) 0.80
Potentiation of radiation-induced regrowth delay by isosorbide dinitrate in FSaII murine tumors. Int J Cancer (2003) 0.80
Role of 2'-2' difluorodeoxycytidine (gemcitabine)-induced cell cycle dysregulation in radio-enhancement of human head and neck squamous cell carcinomas. Radiother Oncol (2004) 0.79
Prevalence of lymph nodes in the apex of level V: a plea against the necessity to dissect the apex of level V in mucosal head and neck cancer. Head Neck (2005) 0.79
Tumor reoxygenation following administration of the EGFR inhibitor, gefitinib, in experimental tumors. Adv Exp Med Biol (2013) 0.78
Use of Xanthinol Nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors. Int J Cancer (2010) 0.78
Radiobiological rationale and patient selection for high-LET radiation in cancer therapy. Radiother Oncol (2004) 0.78
Implant osseointegration in the irradiated mandible. A comparative study in dogs with a microradiographic and histologic assessment. Clin Oral Implants Res (2002) 0.78
Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study. Acta Oncol (2015) 0.78
How to minimize morbidity in radiotherapy of pharyngolaryngeal tumors? Curr Opin Otolaryngol Head Neck Surg (2016) 0.77
Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model. Eur J Nucl Med Mol Imaging (2007) 0.77
Potentiation of radiotherapy by a localized antiangiogenic gene therapy. Radiother Oncol (2013) 0.77
In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors. Radiother Oncol (2003) 0.77
High prevalence of SDHB mutations in head and neck paraganglioma in Belgium. J Hypertens (2008) 0.77
Preclinical safety and antitumor efficacy of insulin combined with irradiation. Radiother Oncol (2006) 0.76
Thyroid status is a key modulator of tumor oxygenation: implication for radiation therapy. Radiat Res (2007) 0.76
Perfluorinated markers for hypoxia detection: synthesis of sulfur-containing precursors and [18F]-labelling. Bioorg Med Chem (2005) 0.76
Synthesis of new 18F-radiolabeled silicon-based nitroimidazole compounds. Bioorg Med Chem (2013) 0.76
Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: a rationale for combination with radiation therapy. Radiother Oncol (2012) 0.76
In regard to Ciernik et al.: Automated functional image-guided radiation treatment planning for rectal cancer (Int J Radiat Oncol Biol Phys 2005;62:893-900). Int J Radiat Oncol Biol Phys (2006) 0.75
Use of 5-[(76)Br]bromo-2'-fluoro-2'-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model. Eur J Nucl Med Mol Imaging (2001) 0.75
Early (72-hour) detection of radiotherapy-induced changes in an experimental tumor model using diffusion-weighted imaging, diffusion tensor imaging, and Q-space imaging parameters: a comparative study. J Magn Reson Imaging (2011) 0.75
(89)Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer: implications for future cancer therapy. Nanomedicine (Lond) (2014) 0.75
High 18F-FDG uptake in a systemic right ventricle after atrial switch. Clin Nucl Med (2015) 0.75
[Multimodalities imaging for target volume definition in radiotherapy]. Bull Cancer (2006) 0.75
4th Würzburg Summer School of Thyroid Cancer Management. Eur J Nucl Med Mol Imaging (2012) 0.75